# Transplant Nephrology Reference Guide

**Programmed by Ratib Mahfouz**

A comprehensive pocket guide for transplant nephrology fellows, covering epidemiology, surgical considerations, immunology, pharmacology, rejection management, and infectious disease protocols.

---

## 1. Epidemiology & Basics

### Statistics
- **Waitlist Candidates**: ~90,000 (Demand)
- **Transplants/Year**: ~25,000 (Supply)
- **Dialysis Mortality**: 15-20% (Annual Risk)
- **Tx Survival (Living)**: 15-20 yrs (Half-Life)
- **Tx Survival (Deceased)**: 8-12 yrs (Half-Life)

### Survival Advantage
*Source: SRTR 2022 Annual Data Report; USRDS Annual Data Report*

Transplantation offers a significant survival advantage over dialysis. Preemptive transplantation (before dialysis) provides the best long-term outcomes.

**5-Year Outcomes Horizon (Survival Probability):**
- **Dialysis**: ~30%
- **Deceased Donor Tx**: ~75%
- **Living Donor Tx**: ~85%

### Donor Types & Risk
- **DBDKT (Donor after Brain Death)**: Heart beating until procurement. Standard risk profile.
- **DCDKT (Donor after Circulatory Death)**: Cardiac arrest prior to organ recovery. **Key Risk**: Higher Delayed Graft Function (DGF) rates due to warm ischemia.
- **LRKT (Living Related)**: Best outcomes due to genetic similarity and elective timing (minimal ischemia).

---

## 2. Surgical & Ischemia

### Cold Ischemia Time (CIT)
*Source: CCF Notes; OPTN*

**Definition**: Time from aortic cross-clamp (donor) to removal from ice (recipient).

- **The Clock**: Every hour counts.
- **Impact**: Prolonged CIT (>18-24 hours) is a major independent risk factor for Delayed Graft Function (DGF).
- **Logistics**: Includes transport time (flying/driving) and time on pump/ice.

### Warm Ischemia Time (WIT)
*Source: CCF Notes*

**Definition**: Time where organ is metabolically active but not perfused.

1.  **Donor Warm Ischemia (First Warm)**
    *   **Specific to DCD**. Time from withdrawal of life support/cardiac arrest until cold perfusion starts.
    *   *High risk for ATN/DGF.*

2.  **Recipient Warm Ischemia (Second Warm)**
    *   Time from removing kidney from ice to reperfusion.
    *   **Target**: < 45 mins (Anastomosis time).

### Surgical Complications Differential
*Differential for oliguria/anuria immediately post-op (Rule of U's)*

- **Urine**: **Urine Leak**. High drain output. Drain creatinine >> Serum creatinine.
- **Ureter**: **Obstruction/Stenosis**. Hydronephrosis on Ultrasound.
- **Vascular**: **Thrombosis**. Renal Artery or Vein thrombosis. **Surgical Emergency**. No flow on Doppler.

---

## 3. Immunology & Allocation

### The Crossmatch (XM)
*Source: STAR 2017 Working Group Report; CCF Care Path*

1.  **Virtual XM (Pre-Op)**
    *   **Method**: Computer comparison of Recipient Anti-HLA Antibody profile (Luminex) vs. Donor HLA typing.
    *   *Predicts compatibility before blood is even mixed.*

2.  **Flow Cytometry XM (Sensitive)**
    *   **Method**: Recipient Serum + Donor Lymphocytes + Fluorescent Anti-IgG tag. Run through a flow cytometer.
    *   *Detects low-level binding (Channel Shift). Positive Flow + Negative CDC = Low risk (monitor closely).*

3.  **Cytotoxic (CDC) XM (Specific)**
    *   **Method**: Recipient Serum + Live Donor Lymphocytes + Rabbit Complement. If antibodies bind, complement lyses the cells.
    *   **Positive CDC = Cell Death = Hyperacute Rejection Risk (Contraindication).**

### Risk Scores
*Source: OPTN/UNOS Policy 8; Kidney Allocation System (KAS)*

- **KDPI (Kidney Donor Profile Index)**: Donor Quality. 0-100%. **Lower is better**. KDPI >85% is "Marginal" (Formerly ECD).
- **cPRA (Calculated Panel Reactive Antibody)**: Sensitization. % of US donors incompatible with recipient. **High Score = Priority Points**.
- **EPTS (Est. Post-Tx Survival)**: Recipient score. Top 20% EPTS candidates receive Top 20% KDPI kidneys to maximize graft life years.

---

## 4. Pharmacology

### Clinical Protocols

#### Low Immunological Risk
*Source: CCF Care Path: Low Risk Protocol*
*Criteria: Primary Tx, Living Donor, cPRA < 20%, Neg Crossmatch.*

- **Induction**: Basiliximab (20mg IV POD 0, 4) OR Thymoglobulin (3 mg/kg total).
- **Tacrolimus**: Start POD 1. Target 8-12 (0-90d), 7-10 (3-6m), 5-8 (>6m).
- **MMF**: 750 mg PO BID.
- **Steroids**: Rapid taper to 5mg daily by ~2 months.

#### Moderate-to-High Risk
*Source: CCF Care Path: High Risk Protocol*
*Criteria: cPRA > 20%, Re-transplant, DSA+, DGF anticipated, African American.*

- **Induction**: Thymoglobulin (3.0 - 6.0 mg/kg total).
- **Tacrolimus**: Start POD 1 or when renal function allows.
- **MMF**: 500-750 mg PO BID (Higher in AA recipients).
- **Steroids**: Standard slow taper.

#### Steroid Avoidance
*Source: CCF Care Path: Steroid Avoidance*

- **Induction**: Thymoglobulin (3.0 - 4.5 mg/kg total).
- **MMF**: Higher dose (1,000 mg PO BID).
- **Steroids**: Rapid withdrawal. Solumedrol POD 0-3, then OFF by Day 4.

### Induction Agents
*Source: KDIGO & CCF Guidelines*

- **Thymoglobulin (ATG)**: Lymphocyte Depleting. Polyclonal antibody (Rabbit). Profound T-cell depletion.
    - **Side Effects**: Cytokine Release Syndrome (Fever/Chills/Rigors), Serum Sickness, Leukopenia, Thrombocytopenia.
- **Basiliximab (Simulect)**: Non-Depleting. IL-2 Receptor Antagonist (CD25). Blocks activation.
    - **Side Effects**: Very well tolerated. Rare hypersensitivity. No Cytokine release.

### Maintenance

#### Calcineurin Inhibitors (CNI)
- **Tacrolimus (Prograf) - IR**:
    - **Side Effects**: Tremor, Nephrotoxicity (afferent constriction), Hyperkalemia, Hypomagnesemia, HTN, NODAT (Diabetes), Hair loss.
    - **Monitor**: Trough 12hr post-dose.
- **Envarsus XR**: Extended release. MeltDose technology. Once daily.
    - Lower Cmax (peak) = **Less Tremor**.
    - Requires 80% of IR dose (increased bioavailability).

#### Antimetabolites & Steroids
- **Mycophenolate (CellCept / Myfortic)**: Inhibits purine synthesis (IMPDH).
    - **Side Effects**: GI Toxicity (Diarrhea/Nausea), Leukopenia, Anemia. **Teratogenic**.
- **Prednisone**:
    - **Side Effects**: Hyperglycemia, Weight Gain, Mood changes, Osteoporosis, HTN, Cataracts, Skin fragility.

### Calculators (Conversion Factors)
- **PO to Sublingual (SL)**: For NPO patients. Ratio **2:1** (PO Dose / 2 = SL Dose).
- **Tacrolimus IR to Envarsus XR**: Conversion factor **0.8** (80% of TDD). Once Daily (AM).

---

## 5. Graft Dysfunction (Rejection)

### Delayed Graft Function (DGF)
*Source: Rao PS et al.; CCF Care Path*

- **Definition**: Requirement for dialysis within the first 7 days post-transplant.
- **Risk Factors**: DCD Donor (Warm Ischemia), Cold Ischemia Time > 24h, High KDPI, High BMI.
- **Management**: Avoid Hypotension, Adjust meds (Hold ACEi), **Biopsy** if no recovery by Day 7-14 to rule out rejection.

### TCMR (T-Cell Mediated Rejection)
*Source: CCF Protocol: Rejection*
*Tubulitis, Interstitial Inflammation*

- **Borderline/IA**: Pulse Solumedrol 500mg x 3.
- **Severe/Vascular (II/III)**: Thymoglobulin 1.5 mg/kg/day (Target 4-7 mg/kg total).
- Followed by Oral Steroid Taper.

### ABMR (Antibody Mediated Rejection)
*Source: CCF Protocol: Rejection*
*DSA, C4d+, Microvascular Inflammation*

- **Plasmapheresis**: x 6 sessions (3/week x 2 weeks).
- **IVIG**: 0.5 g/kg after each Plex (Total 2 g/kg).
- **+/- Rituximab**: Anti-CD20.

---

## 6. Infectious Disease

### CMV Prophylaxis & Treatment
*Source: CCF Care Path: Viral Infections*

- **High Risk (D+/R-)**: Primary. Valganciclovir 900mg daily x **6 months**.
- **Intermediate (R+)**: Reactivation. Valganciclovir 900mg daily x **3 months**.
- **Treatment of CMV Disease**:
    - **Valganciclovir**: 900 mg BID (Treatment dose) until negative PCR x 2 weeks.
    - **IV Ganciclovir**: 5 mg/kg q12h. Use for severe disease/malabsorption.
    - Reduce Immunosuppression (Stop MMF).

### PTLD (Post-Transplant Lymphoproliferative Disorder)
*Source: CCF Notes; AST Guidelines*

- **Definition**: Malignancy driven by EBV proliferation of B-cells.
- **Risk Factors**: EBV D+/R- (Highest), Heavy T-cell depletion (Thymo).
- **Presentation**: Fever, Weight Loss, Lymphadenopathy, Rise in Creatinine.
- **Management**:
    1.  **Reduce Immunosuppression**: 1st line (Regression possible).
    2.  **Rituximab**: Anti-CD20 monoclonal antibody.
    3.  **Chemotherapy**: (CHOP) for non-responders.

### PJP Prophylaxis
*Source: CCF Care Path: PJP*

- **Drug**: Bactrim (TMP-SMX). 1 SS Daily OR 1 DS 3x/week.
- **Duration**: Life of allograft (or min 18 months).
- **Sulfa Allergy**: Dapsone 100mg daily or Atovaquone or Pentamidine.

### Fungal / HSV
*Source: CCF Care Path*

- **Fungal (Thrush)**: Nystatin or Clotrimazole x 1 month.
- **HSV / VZV**: Acyclovir 400mg BID x 3 months (if not on Valcyte).

### BK Virus (Polyomavirus)
*Source: CCF Care Path: BKV*

- **Screening**: Monthly PCR up to 6 months, then q3 months.
- **Management (Stepwise)**:
    1.  Reduce Immunosuppression (30-50%).
    2.  Reduce Tacrolimus target to **4-7 ng/mL**.
    3.  Decrease MMF dose by 50%.
    4.  Consider Leflunomide or IVIG (Second line).

---

## 7. Landmark Studies
*Key Trials in Transplant Nephrology*

### Immunosuppression Maintenance
**ELITE-Symphony** (Ekberg et al., NEJM 2007)
- **Population**: 1,645 de novo kidney transplant recipients
- **Intervention**: Low-dose Tacrolimus + MMF + Steroids + Daclizumab
- **Comparison**: Standard-dose Cyclosporine, Low-dose Cyclosporine, or Low-dose Sirolimus regimens
- **Outcome**: Low-dose Tacrolimus had the best eGFR, lowest acute rejection rate, and highest graft survival.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/18094377/)

### CNI-Sparing
**BENEFIT Trial** (Vincenti et al., Am J Transplant 2010)
- **Population**: 666 kidney transplant recipients (standard criteria/living donors)
- **Intervention**: Belatacept (More Intensive or Less Intensive)
- **Comparison**: Cyclosporine (Standard Care)
- **Outcome**: Belatacept showed superior renal function and metabolic profiles but higher rates/grades of early acute rejection.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/20415897/)

### Induction
**Brennan Induction** (Brennan et al., NEJM 2006)
- **Population**: 278 high-risk kidney transplant recipients
- **Intervention**: Rabbit Anti-Thymocyte Globulin (rATG) induction
- **Comparison**: Basiliximab (IL-2 RA) induction
- **Outcome**: rATG significantly reduced acute rejection (15.6% vs 25.5%) but increased infection risk; survival was similar.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/17093248/)

### Steroid Withdrawal
**Woodle Steroid Withdrawal** (Woodle et al., Ann Surg 2008)
- **Population**: 386 low-to-moderate risk recipients
- **Intervention**: Early Steroid Withdrawal (stopped by day 7)
- **Comparison**: Chronic Corticosteroid Maintenance
- **Outcome**: No difference in patient/graft survival at 5 years. Withdrawal group had slightly higher rejection but better metabolic outcomes.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/18936577/)

### Special Populations
**HOPE Study** (Durand et al., NEJM 2019)
- **Population**: 75 HIV-positive kidney transplant candidates
- **Intervention**: Kidneys from HIV-positive deceased donors
- **Comparison**: Kidneys from HIV-negative deceased donors
- **Outcome**: No significant difference in graft survival or rejection, validating the safety of HIV-to-HIV transplantation.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/30893539/)

### mTOR Inhibitors
**TRANSFORM Study** (Pascual et al., J Am Soc Nephrol 2018)
- **Population**: 2,037 de novo recipients
- **Intervention**: Everolimus + Reduced-exposure CNI
- **Comparison**: Mycophenolic Acid (MPA) + Standard-exposure CNI
- **Outcome**: Everolimus regimen was non-inferior for composite endpoint (rejection/graft dysfunction) with different side-effect profile (wound issues vs viral).
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/29875199/)

### Historical/Antimetabolites
**Tricontinental MMF** (The Tricontinental Study Group, Lancet 1996)
- **Population**: 503 cadaveric kidney recipients
- **Intervention**: Mycophenolate Mofetil (MMF)
- **Comparison**: Azathioprine + Cyclosporine + Steroids
- **Outcome**: MMF significantly reduced biopsy-proven acute rejection compared to Azathioprine.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/8623181/)

### Desensitization
**Montgomery Desensitization** (Montgomery et al., NEJM 2011)
- **Population**: 211 HLA-sensitized patients with incompatible living donor
- **Intervention**: Desensitization + Live Donor Transplant
- **Comparison**: Waitlist (Dialysis or eventual compatible transplant)
- **Outcome**: Significant survival benefit for desensitized patients compared to those remaining on dialysis/waitlist.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/21793744/)

### Infectious Disease
**IMPACT Study** (Humar et al., Am J Transplant 2010)
- **Population**: 318 high-risk (CMV D+/R-) recipients
- **Intervention**: Valganciclovir prophylaxis for 200 days
- **Comparison**: Valganciclovir prophylaxis for 100 days
- **Outcome**: 200-day prophylaxis significantly reduced CMV disease at 12 months without increased toxicity.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/20420626/)

### CNI Minimization
**CAESAR Study** (Ekberg et al., Am J Transplant 2007)
- **Population**: 536 de novo recipients
- **Intervention**: Cyclosporine Withdrawal (stopped by month 6)
- **Comparison**: Low-dose or Standard-dose Cyclosporine maintenance
- **Outcome**: Complete Cyclosporine withdrawal led to significantly higher acute rejection rates.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/17229079/)

### Pediatrics
**TWIST Study** (Grenda et al., Am J Transplant 2010)
- **Population**: Pediatric recipients (low risk)
- **Intervention**: Steroid-free regimen (Tac + MMF + Daclizumab)
- **Comparison**: Standard Steroid Maintenance
- **Outcome**: Steroid-free group had better linear growth with no increased risk of rejection or graft loss.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/20420639/)

### Conversion Strategies
**ZEUS Study** (Budde et al., Lancet 2011)
- **Population**: 300 de novo recipients
- **Intervention**: Early conversion to Everolimus (4.5 months) + CNI elimination
- **Comparison**: Continue Cyclosporine
- **Outcome**: Conversion improved renal function (GFR) but was associated with a higher rate of mild acute rejection.
- [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/21658448/)

---

## 8. Mechanism of Action Diagram

![Mechanism of Action of Immunosuppressive Drugs](C:/Users/MAHFOUR2/.gemini/antigravity/brain/de0594db-65f5-4e11-ac83-5dbe5d4c7fb4/immunosuppression_mechanism_diagram_1764018649224.png)

*Figure: Simplified schematic of the 3-Signal Model of T-Cell Activation and sites of action for major immunosuppressive agents.*

